Researchers Behind Spinraza Win Breakthrough Prize [Forbes]
Ionis Pharmaceuticals, Inc. (IONS)
Last ionis pharmaceuticals, inc. earnings: 2/26 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
ionispharma.com
Company Research
Source: Forbes
C. Frank Bennett, the head of research at Ionis Pharmaceuticals, and Adrian R. Krainer, the St. Giles Foundation professor at Cold Spring Harbor Laboratory, will share a $3 million Breakthrough Prize for their role in developing Spinraza, a drug against spinal muscular atrophy that was invented by Ionis and is marketed by Biogen. The Breakthrough Prizes, an “Oscars of ” sponsored by Sergey Brin, Priscilla Chan and Mark Zuckerberg, Ma Huateng, Yuri and Julia Milner and Anne Wojcicki, pay out larger amounts than any other scientific award. This year, a total of $22 million will be awarded in a televised awards ceremony on November 4. Breakthrough awards will also be given to Angelika Amon, of the Massachusetts Institute of Technology and Howard Hughes Medical Institute, for research into how having abnormal numbers of chromosomes disrupts cell function; to Xiaowei Zhuang, of Harvard University and Howard Hughes Medical Institute, for using super-resolution imaging to study cells; and Zh
Show less
Read more
Impact Snapshot
Event Time:
IONS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
IONS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
IONS alerts
High impacting Ionis Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
IONS
News
- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) had its price target lowered by analysts at Piper Sandler from $65.00 to $62.00. They now have an "overweight" rating on the stock.MarketBeat
- Flamingo Therapeutics Announces Oral Presentation at AACR Special Conference in Cancer Research on RNAs as Drivers, Targets, and Therapeutics in Cancer [Yahoo! Finance]Yahoo! Finance
- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating.MarketBeat
- Company News for Nov 7, 2024 [Yahoo! Finance]Yahoo! Finance
- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) had its price target lowered by analysts at Wells Fargo & Company from $82.00 to $77.00. They now have an "overweight" rating on the stock.MarketBeat
IONS
Earnings
- 11/6/24 - Beat
IONS
Sec Filings
- 11/13/24 - Form 144/A
- 11/12/24 - Form 144
- 11/12/24 - Form 144
- IONS's page on the SEC website